Ozempic and GLP-1 Drugs for Alcohol
Semaglutide has reduced craving and some drinking outcomes in trials, but it is not approved for alcohol use disorder. Understand the findings, safety questions and treatment options available now.
Battling addiction & ready for help?
Can GLP-1 Drugs Help Reduce Drinking?
Semaglutide has reduced alcohol craving and some drinking outcomes in randomized trials. That makes drugs such as Ozempic a serious research question for alcohol use disorder, or AUD. It does not make them an established replacement for alcohol treatment. The studies have important limits, and semaglutide’s approved indications do not include AUD.[1][2][3][4]
If you already take a GLP-1 medicine and notice less interest in drinking, tell your clinician. The change may be useful to discuss alongside your drinking goals, side effects and other medicines. Do not change a prescription or assume that reduced craving protects you from alcohol-related harm.
Withdrawal needs a separate plan. If you drink heavily and regularly, get medical advice before suddenly stopping or sharply cutting back. Withdrawal can cause seizures and severe confusion. Assessment, monitoring and medication can reduce complications, but cannot make withdrawal risk-free. A GLP-1 medicine is not a substitute for withdrawal treatment.[5] Call 911 for a seizure or severe confusion.
- Semaglutide is promising, but still being studied for AUD. Its approved labels cover other conditions.[3][4]
- The trials answer different questions. A small study tested drinking in a laboratory. A later study tested heavy drinking days in people with AUD and obesity.[1][2]
- A class-wide benefit cannot be assumed. An exenatide trial did not meet its main drinking outcome.[7]
- Medical-record studies show associations. They cannot establish that a GLP-1 drug is better than an approved AUD medicine.[12]
- You do not have to wait for new research to get help. Counseling and approved alcohol medications are available now.[6]
What GLP-1 Drugs Are
GLP-1 stands for glucagon-like peptide-1. Semaglutide activates GLP-1 receptors, helping regulate blood glucose and slowing stomach emptying. It can also reduce calorie intake. These effects explain why it is used for diabetes and weight management, although each product has its own indications.[3][4]
Ozempic and Wegovy contain semaglutide. Ozempic’s indications include type 2 diabetes and certain cardiovascular and kidney risk reductions. Wegovy’s indications include weight management and cardiovascular risk reduction in eligible patients. Its injection also has a specified metabolic liver disease indication. These approvals should not be read as approval for alcohol-related liver disease or AUD.[3][4]
The alcohol trials below used weekly semaglutide injections. Their results do not automatically apply to every formulation, dose or medicine in the broader family.[1][2] Tirzepatide activates both GIP and GLP-1 receptors. It has encouraging observational findings, but those findings answer a different question from a randomized AUD treatment trial.[11]
What the Semaglutide Trials Found
The 2025 Pilot Tested Craving and Drinking Intensity
A JAMA Psychiatry trial randomized 48 adults with AUD who were not seeking treatment to semaglutide or placebo for nine weeks.[1] Participants receiving semaglutide consumed less alcohol in a laboratory session and reported lower craving and fewer drinks per drinking day. However, average drinks per calendar day and the number of drinking days did not significantly change.[1]
That distinction matters when reading “reduced drinking.” Amount consumed, frequency and craving are separate outcomes. A better result for craving does not establish a better result for drinking frequency. The study was too small and short to settle longer-term treatment effectiveness.[1]
The 2026 Trial Studied AUD With Obesity
A Lancet trial enrolled 108 treatment-seeking adults with moderate-to-severe AUD and obesity. Both groups received cognitive behavioral therapy. Over 26 weeks, the proportion of heavy drinking days fell by 41.1 percentage points with semaglutide and 26.4 with placebo.[2] The adjusted treatment difference was 13.7 percentage points, with a 95% confidence interval of 5.4–22.0 points favoring semaglutide.[2]
Overall, 88 participants completed treatment.[2] Gastrointestinal side effects were more common with semaglutide and generally mild to moderate. The findings support further development, but they do not establish the same benefit in people without obesity or show that semaglutide outperforms naltrexone or acamprosate.[2]
| Study feature | 2025 pilot | 2026 trial |
|---|---|---|
| Participants | 48 adults, not seeking treatment.[1] | 108 adults with AUD and obesity, seeking treatment.[2] |
| Duration and background care | Nine weeks of outpatient study visits.[1] | Twenty-six weeks, with cognitive behavioral therapy in both groups.[2] |
| Study regimen | The trial used weekly injections, increased from 0.25 mg to 1 mg.[1] The laboratory outcome was assessed at a trial dose of 0.5 mg.[1] | The trial used weekly injections with a 2.4 mg treatment dose.[2] |
| Main question | Alcohol consumption in a laboratory session.[1] | Reduction in heavy drinking days.[2] |
These are descriptions of research regimens, not instructions for treating yourself. A prescriber must evaluate the medicine, indication and monitoring appropriate to your circumstances.
The Earlier Exenatide Trial Was Not Positive Overall
In a 2022 trial, 127 treatment-seeking people with AUD received weekly exenatide or placebo, with cognitive behavioral therapy, for 26 weeks. Exenatide did not significantly reduce heavy drinking days compared with placebo. Exploratory analyses suggested benefit in the subgroup with obesity, but a subgroup finding cannot turn a negative primary result into proof of effectiveness.[7]
The study also found changes in brain responses to alcohol cues. A measurable brain change is informative for researchers, but it is not the same as demonstrating better drinking outcomes for the whole treatment group.[7]
How GLP-1 Drugs Might Affect Alcohol Cravings
Researchers Are Studying Reward Circuits
Animal work suggests GLP-1 signaling can affect alcohol’s rewarding properties. A 2025 rodent study examined a brain region called the lateral septum. In rodents, activating GLP-1 receptors in the lateral septum reduced alcohol intake and some alcohol-related reward responses, including dopamine release in another reward-related region.[8]
In that experiment, reduced alcohol intake occurred without reduced food or water intake. This supports studying a mechanism beyond appetite alone. It does not prove that the same circuit explains reduced drinking in people. Human imaging findings and animal experiments help generate explanations that still need clinical testing.[7][8]
Slower Alcohol Absorption May Also Matter
A small study compared 20 people with obesity, half taking a GLP-1 medicine and half in a control group, after an alcohol challenge.[9] The GLP-1 group had a delayed rise in breath alcohol and subjective effects. This suggests that changes outside the brain, such as slower stomach emptying, may contribute.[9]
The result does not mean alcohol becomes harmless or that delayed effects make driving safe. The study was preliminary and did not establish a safe drinking amount. Brain and digestive effects may both matter, but researchers have not fully explained their contributions in people.[9]
What Medical-Record Studies Add
Researchers have also compared outcomes among people prescribed these medicines in routine care. Such studies can examine larger groups and longer follow-up than an early trial. Their weakness is that treatment is not randomly assigned. Differences in health, access to care and the reasons for prescribing can influence the findings.
| Question | Finding | Important limit |
|---|---|---|
| New AUD diagnoses | A 2026 review found a pooled hazard ratio of 0.72, or a 28% lower relative hazard, across three observational cohorts reporting this outcome.[10] | The review included five cohorts overall. The other two studied alcohol-related hospitalization, where the pooled result was not statistically significant.[10] |
| Differences between medicines | Among people with type 2 diabetes and no prior AUD diagnosis, tirzepatide and semaglutide were associated with lower hazards of a new diagnosis than DPP-4 inhibitors over eighteen months. The hazard ratios were 0.47 and 0.68, respectively.[11] | Liraglutide and dulaglutide did not show a significant difference. This was medical-record analysis, not random assignment or treatment of established AUD.[11] |
| Relapse after treatment | A Stanford cohort associated GLP-1 treatment with a lower one-year AUD relapse rate than approved AUD medicines in patients with concurrent metabolic problems.[12] | Groups differed clinically. Matching cannot eliminate every confounder or prove that one treatment is superior.[12] |
A hazard ratio compares event rates over follow-up. A lower relative hazard does not tell you the absolute number of people who avoided AUD. The starting risk and follow-up period matter, and a recorded diagnosis is not a direct measure of how much someone drank.[10][11]
Possible Liver Benefits Need Careful Interpretation
A U.S. Veterans study matched 8,040 GLP-1 medicine users with 8,040 nonusers who had positive alcohol screens.[13] GLP-1 use was associated with fewer liver-related complications and deaths. This was an observational comparison, so it does not prove that the medicine caused those differences.[13]
Another medical-record study examined people with AUD and type 2 diabetes. Associations with cirrhosis and related complications differed by the comparison medicine. For example, the comparison with metformin did not reach statistical significance. It would be misleading to summarize every comparison as a proven liver benefit.[14]
The Stanford relapse study excluded people with advanced liver disease near diagnosis, and its cirrhosis result was not statistically significant.[12] These results cannot establish treatment safety or effectiveness for someone with advanced alcohol-related liver disease. A clinician needs to evaluate that condition directly.
What Remains Uncertain
The main unanswered questions include who benefits most, how long improvement lasts, which formulation and dose are appropriate, and how treatment compares with established AUD medicines. The studies have included people with heavy drinking. The limitation is how far results from particular trial populations can be applied to other patients.[1][2][7]
Discussing the 2025 pilot with UNC Health, endocrinologist and study coauthor Klara Klein called for “Larger and longer studies in broader populations” to clarify safety and effectiveness.[15] The 2026 trial adds evidence, but its participants all had obesity and received therapy. It does not answer every question about broader use.[2]
There is also early interest in smoking and other substance-use outcomes. The 2025 pilot reported reduced cigarette use in a small subgroup. That exploratory result is not enough to treat semaglutide as a proven smoking-cessation medicine.[1]
Safety Questions to Discuss With a Prescriber
Semaglutide can cause nausea, vomiting, diarrhea, constipation and abdominal discomfort. Its prescribing information also warns about pancreatitis, gallbladder problems, dehydration-related kidney injury and sometimes severe gastrointestinal reactions. Severe gastroparesis, a condition involving very slow stomach emptying, is an important prescribing concern.[3][4]
The boxed warning concerns thyroid C-cell tumors observed in rodents. Whether semaglutide causes these tumors in humans is unknown. The medicine is contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, known as MEN 2.[3][4]
Tell the prescriber about pregnancy plans, eye disease related to diabetes, kidney problems, previous pancreatitis, all medicines and any planned procedure requiring anesthesia. Insulin and certain other diabetes medicines can increase the risk of low blood sugar when used with semaglutide. This is not a complete list of prescribing considerations.[3][4]
Do not assume a drop in craving makes it safe to stop heavy drinking abruptly. Withdrawal risk depends on physical dependence and other clinical factors, not how appealing alcohol currently feels. Ask for an alcohol assessment and a withdrawal plan when appropriate.[5]
Use a Licensed Prescriber and Pharmacy
FDA warns that compounded GLP-1 products do not undergo its premarket review for safety, effectiveness and quality. It has received reports of dosing errors, including some requiring hospitalization. Compounded treatment may meet a specific medical need, but it should not be advertised as automatically equivalent to an FDA-approved product.[16]
FDA advises obtaining a prescription and using a state-licensed pharmacy. A website selling medicine without appropriate screening or a prescription is a warning sign. Ask the prescriber and pharmacist exactly what product you would receive and how to use it. Do not buy products sold as “research” chemicals for personal treatment.[16]
Finding Alcohol Treatment Near You or Online
You can raise the GLP-1 question with primary care, an addiction medicine clinician or the professional already treating your diabetes or weight-related condition. A useful starting point is: “I’m concerned about my drinking. Can we assess it and compare the treatment options, including what this research might mean for me?”
When looking for an alcohol treatment provider near you or online, ask whether they assess withdrawal risk, provide or coordinate medication care, and offer follow-up. Confirm that the clinician can treat people in your state. An online counseling service is not automatically a prescribing service or a substitute for urgent medical care.
Ask for the total cost, what insurance will cover for your particular diagnosis and product, and how follow-up is billed. Approval for one condition does not establish coverage for another. Confirm the answer before paying rather than relying on a general price claim.
NIAAA’s treatment guidance describes behavioral treatments and three FDA-approved AUD medicines: naltrexone, acamprosate and disulfiram. Their roles differ, and the right choice depends on your goals and health. Treatment may combine medication, counseling and other support.[6] Our guide to alcohol medications explains the established options.
If you are specifically interested in targeted naltrexone, the Sinclair Method guide explains its evidence and prescribing considerations. If stopping or reducing drinking is the immediate concern, read about medically supervised alcohol withdrawal care. Withdrawal care can be one step toward continuing treatment, not the whole treatment plan.[5]
You can ask for help before you know which treatment you need.
If you are in emotional distress or thinking about suicide, call or text 988. Call 911 for an immediate medical emergency.
Frequently asked questions
Does Ozempic Really Reduce Alcohol Cravings?
Is Semaglutide Approved for Alcohol Use Disorder?
How Much Did Drinking Change in the Trials?
Which GLP-1 Drug Works Best for Drinking?
The evidence does not establish a best drug for treating AUD. Observational comparisons of new diagnoses cannot substitute for head-to-head randomized treatment trials. Exenatide also failed to improve the main drinking outcome in its overall trial population, despite an exploratory subgroup signal.[7][11]
Can a GLP-1 Drug Replace Naltrexone or Another Alcohol Medicine?
Do not replace prescribed treatment on your own. NIAAA describes naltrexone, acamprosate and disulfiram as approved AUD medicines, with different clinical roles.[6] Discuss what a GLP-1 medicine would add, especially if you have another condition for which it may be prescribed. Our alcohol medication guide explains established options.
Is It Safe to Drink Alcohol While Taking Ozempic?
There is no single answer for everyone. Your drinking, other medicines, diabetes management and health conditions matter. A small study found delayed alcohol effects in GLP-1 users, which does not establish safety.[9] Tell your prescriber how much you drink. If you drink heavily and regularly, seek medical advice before abruptly stopping because withdrawal can be dangerous.[5]
Get Treatment Help
If you or someone you love is struggling with addiction, getting help is just a phone call away, or consider trying therapy online with BetterHelp.
Exclusive offer: 20% Off BetterHelp*Following links to the BetterHelp website may earn us a commission that helps us manage and maintain AddictionHelp.com. *Get 20% off your first month of BetterHelp. Offer valid for new BetterHelp users only. Offer cannot be combined with insurance.
- Fact-Checked
- Editor
